Venus Concept

Venus Concept, Inc. develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related practice enhancement services. Its product portfolio consists of aesthetic device platforms which includes venus versa, venus legacy, venus velocity, venus fiore, venus viva, venus freeze plus, and venus bliss. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Venus Concept surpasses revenue expectations in Q1 2024 earnings call

Venus Concept's Q1 2024 performance showed resilience with revenue exceeding expectations despite challenges. Strategic initiatives to exit unprofitable markets and focus on cash system sales led to improved financial metrics. The company's progress in key initiatives and financial improvements demonstrate a commitment to long-term growth and stability.

Venus Concept reports mixed Q3 results, eyes growth opportunities

Venus Concept faced revenue challenges in Q3 2024, but saw growth in distributor sales and progress in restructuring efforts. Despite financial setbacks, the company is optimistic about new product launches, regulatory clearances, and debt reduction strategies. Analyst interest remains high in revenue mix, new product launches, market strengths, and debt management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

The FDA has given 510(k) clearance to Venus Concept Inc's (NASDAQ: VERO) Venus Freedom device for pain management. Venus Freedom is a noninvasive, non-ablative device with three applicators to deliver non-thermal radiofrequency energy combined with massage and magnetic field pulses.

Venus Concept's Pain Management Device Scores FDA Nod

TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market the Venus Freedom device in the United States.

Venus Concept Receives FDA 510(k) Clearance for the Venus Freedom™

TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022.

Venus Concept Appoints Ross J. Portaro as President of Global Sales

TORONTO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that third quarter of fiscal year 2021 financial results will be released before the market opens on Friday, November 12, 2021.

Venus Concept to Release Third Quarter of Fiscal Year 2021 Financial Results on November 12, 2021

TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13th-15th. Management's presentation will be available on-demand beginning on Monday, September 13th at 7:00 a.m. Eastern Time. Management will participate in virtual investor meetings on Tuesday, September 14th throughout the day.

Venus Concept Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Venus Concept Inc. (VERO) CEO Dom Serafino on Q2 2021 Results - Earnings Call Transcript

Venus Concept Inc's (NASDAQ: VERO) Q2 sales increased 52% Y/Y to $25.8 million, beating the consensus of $24.26 million. The increase by product category was driven by a 71% increase in lease revenue, a 29% increase in systems revenue, an 86% increase in products revenue, and a 5% increase in services revenue.

Venus Concept Stock Trades Higher After Lifting FY21 Sales Outlook

Venus Concept (VERO) delivered earnings and revenue surprises of 71.43% and 6.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Venus Concept (VERO) Reports Q2 Loss, Tops Revenue Estimates

The shares of Venus Concept Inc. (NASDAQ: VERO) increased by over 15% pre-market. This is why it happened.

Venus Concept Shares Increase Over 15% Pre-Market: Why It Happened

Shares of Venus Concept (NASDAQ:VERO) rose 15.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 102.56% year over year to $0.01, which beat the estimate of ($0.12).

Recap: Venus Concept Q2 Earnings

TORONTO, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2021.

Venus Concept Announces Second Quarter 2021 Financial Results; Increases Fiscal Year 2021 Revenue Guidance

Venus Concept (VERO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Venus Concept (VERO) Report Negative Earnings Next Week? What You Should Know

Venus is a supplier of medical aesthetics products on a buy or lease basis that merged with Restoration Hair Robotics in November 2019. Nearly 2 years on however, Venus' enlarged business is yet to hit its stride, burdened by debt and pandemic headwinds.

Venus Concept: Pandemic And Debt Obscure Promise Of Medical Aesthetics Business

TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a medical device license issued by Health Canada to market the Venus Fiore Feminine Health System in Canada. This follows the receipt of CE Mark for the Venus Fiore Feminine Health System in March 2020. The Company intends to begin a limited launch of the Venus Fiore in Canada and the European Union in the third quarter of 2021.

Venus Concept Announces Health Canada Authorization and CE Mark for Venus Fiore® Feminine Health System

TORONTO, July 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the Ladenburg Thalmann Healthcare Conference.

Venus Concept Inc. to Participate in the Ladenburg Thalmann Healthcare Conference on July 13th

TORONTO, July 08, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that second quarter of fiscal year 2021 financial results will be released before the market opens on Friday, August 13, 2021.

Venus Concept to Release Second Quarter of Fiscal Year 2021 Financial Results on August 13, 2021

The stock price of Venus Concept Inc (NASDAQ: VERO) increased by over 9% pre-market. This is why it happened.

VERO Stock Price Increases Over 9% Pre-Market: Why It Happened

Venus Concept Inc. (VERO) CEO Domenic Serafino on Q1 2021 Results - Earnings Call Transcript

TORONTO, May 17, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2021.

Venus Concept Announces First Quarter of 2021 Financial Results; Increases Fiscal Year 2021 Revenue Guidance

Venus Concept (VERO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Venus Concept (VERO)

TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that first quarter of fiscal year 2021 financial results will be released after the market closes on Monday, May 17, 2021.

Venus Concept to Release First Quarter of Fiscal Year 2021 Financial Results on May 17, 2021

Venus Concept Inc. (VERO) CEO Domenic Serafino on Q4 2020 Results - Earnings Call Transcript

Shares of Venus Concept (NASDAQ:VERO) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 74.77% over the past year to ($0.27), which missed the estimate of ($0.19).

Venus Concept: Q4 Earnings Insights

TORONTO, March 29, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2020.

Venus Concept Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Reaffirms Fiscal Year 2021 Revenue Guidance

TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will attend and present at the H.C. Wainwright Annual Global LifeSciences Conference, which is being held virtually from March 9th-10th. Management's presentation will be available on-demand beginning on Tuesday, March 9th at 7:00 a.m. Eastern Time.

News for Venus Concept Stock (VERO)